Riskpilot← Back to searchSign inGet full accessVEN KLINIKKEN AS
ASActiveOrg 825621822Falkenborgvegen 9, 7044 TrondheimBeauty care and other beauty treatment activities · NACE 9622Est. 20202 employeesvenklinikken.no
Revenue 2024
NOK 3,6M
-4% vs 2023
EBITDA margin
4.9%
+678% vs 2023
Equity ratio
47.0%
Financial strength
Net profit 2024
NOK 131K
+541% vs 2023
| Revenue | NOK 3,6M | -4% |
| EBITDA | NOK 173K | +678% |
| Net profit | NOK 131K | +541% |
| Total assets | NOK 1,2M | +20% |
| Equity | NOK 553K | +31% |
| Employees | 2 | — |
Legal name
VEN KLINIKKEN AS
Org number
825621822
Legal form
Aksjeselskap
NACE code
9622 · Beauty care and other beauty treatment activities
Founded
11. september 2020
Share capital
NOK 37 500
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Helsetjenester, kroppspleie og fysisk velvære.
Address
Falkenborgvegen 9, 7044 Trondheim
Website
venklinikken.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 328 | 1 662 | 2 956 | 3 688 | 3 554 |
| Staff expenses | −0 | −462 | −1 280 | −1 555 | −1 501 |
| EBITDA | 3 | 297 | 191 | −30 | 173 |
| Depreciation & amort. | −0 | −0 | −3 | −3 | −3 |
| EBIT | 3 | 297 | 188 | −33 | 170 |
| Net financials | −6 | −10 | −6 | −4 | 1 |
| Profit before tax | −3 | 286 | 183 | −38 | 170 |
| Tax | −1 | 64 | 41 | −8 | 39 |
| Net profit | −2 | 223 | 142 | −30 | 131 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 277 | 674 | 955 | 982 | 1 177 |
| Equity | 88 | 310 | 452 | 423 | 553 |
| Long-term debt | 151 | 98 | 45 | 0 | 2 |
| Short-term debt | 38 | 266 | 458 | 560 | 622 |
| Total debt | 189 | 364 | 503 | 560 | 624 |
EBITDA margin
4.9%
This company
15.8%
Market median
-69% vs market
20202024
Equity ratio
47.0%
This company
38.2%
Market median
+23% vs market
20202024
Return on equity
23.6%
This company
18.4%
Market median
+28% vs market
20202024
Net profit margin
3.7%
This company
8.1%
Market median
-54% vs market
20202024
Asset turnover
3.02×
This company
1.12×
Market median
+170% vs market
20202024
Debt / equity
1.13×
This company
0.62×
Market median
-82% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-09-03 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JF Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 10% | 10% | 2022 | |
| Company | 10% | 10% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Sandgrind Holding As
VEN KLINIKKEN AS Board members of VEN KLINIKKEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Julie Flaamo | Chief Executive Officer | 0 companies |
| Roy Andre Sandgrind | Board of Directors | 0 companies |
| Emil Holst Volden | Chairman | 0 companies |
| Christine Berger | Board of Directors | 0 companies |
| Christine Berger Volden | Board of Directors | 0 companies |